Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study.

Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study.

<p><strong>Objectives:</strong> Recruitment to pragmatic trials is often difficult, and little is known about factors associated with key participation and treatment decisions. These were explored in the Prostate cancer testing and Treatment (ProtecT) study.</p> <...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Donovan, JL, Opmeer, B, Young, GJ, Mills, N, Martin, RM, Lane, JA, Metcalfe, C, Peters, TJ, Davis, M, Turner, EL, Walsh, E, Neal, DE, Hamdy, FC, ProtecT Study Group
التنسيق:	Journal article
اللغة:	English
منشور في:	Elsevier 2019

مواد مشابهة

A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial
حسب: Donovan, JL, وآخرون
منشور في: (2017)

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
حسب: J. Donovan, وآخرون
منشور في: (2003-01-01)

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial
حسب: S. Sanghera, وآخرون
منشور في: (2020-10-01)

Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study
حسب: Young, GJ, وآخرون
منشور في: (2017)

Addressing patient treatment preferences at trial recruitment.
حسب: Mills, N, وآخرون
منشور في: (2011)

Exploring treatment preferences facilitated recruitment to randomized controlled trials
حسب: Mills, N, وآخرون
منشور في: (2011)

Exploring treatment preferences facilitated recruitment to randomized controlled trials.
حسب: Mills, N, وآخرون
منشور في: (2011)

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
حسب: Lane, A, وآخرون
منشور في: (2016)

Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified.
حسب: Down, L, وآخرون
منشور في: (2009)

Addressing patient treatment preferences at trial recruitment
حسب: Mills Nicola, وآخرون
منشور في: (2011-12-01)

Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).
حسب: Donovan, J, وآخرون
منشور في: (2003)

Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen
حسب: Harrison, S, وآخرون
منشور في: (2020)

The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation
حسب: Rooshenas, L, وآخرون
منشور في: (2018)

A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study).
حسب: Mills, N, وآخرون
منشور في: (2006)

Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study).
حسب: Turner, E, وآخرون
منشور في: (2011)

Radiotherapy for prostate cancer: is it 'what you do' or 'the way that you do it'? A UK perspective on technique and quality assurance.
حسب: Mason, MD, وآخرون
منشور في: (2016)

Low risk research using routinely collected identifiable health information without informed consent: encounters with the Patient Information Advisory Group.
حسب: Metcalfe, C, وآخرون
منشور في: (2008)

Informed consent in randomised controlled trials: development and preliminary evaluation of a measure of participatory and informed consent (PIC)
حسب: Wade, J, وآخرون
منشور في: (2017)

Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial.
حسب: Walsh, E, وآخرون
منشور في: (2016)

Experiences and decision processes during PSA testing and prostate biopsy: A qualitative study
حسب: Avery, K, وآخرون
منشور في: (2007)

Seasonal variation in prostate-specific antigen levels: A large cross-sectional study of men in the UK
حسب: Down, L, وآخرون
منشور في: (2011)

Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?
حسب: Avery, K, وآخرون
منشور في: (2008)

Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
حسب: Macefield, R, وآخرون
منشور في: (2009)

Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK.
حسب: Down, L, وآخرون
منشور في: (2011)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
حسب: Lane, J, وآخرون
منشور في: (2010)

Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer
حسب: Hamdy, FC, وآخرون
منشور في: (2023)

ProDiet: A phase II randomized placebo-controlled trial of green tea catechins and lycopene in men at increased risk of prostate cancer
حسب: Lane, JA, وآخرون
منشور في: (2018)

ASSOCIATIONS OF SEXUAL DYSFUNCTION WITH LOCALIZED AND ADVANCED PROSTATE CANCER: A CASE-CONTROL STUDY NESTED WITHIN THE UK POPULATION-BASED PROTECT (PROSTATE TESTING FOR CANCER AND TREATMENT) STUDY
حسب: Collin, S, وآخرون
منشور في: (2009)

Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: The CAP randomized clinical trial
حسب: Martin, RM, وآخرون
منشور في: (2018)

Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer
حسب: Donovan, J, وآخرون
منشور في: (2016)

Ethics of clinical trials from bayesian perspective: randomisation to clinical trials may solve dilemma of treatment choice in prostate cancer.
حسب: Hamdy, F, وآخرون
منشور في: (2003)

The protect trial - Evaluating the effectiveness of treatments for clinically localised prostate cancer and associated molecular and genetic epidemiology studies
حسب: Lane, J, وآخرون
منشور في: (2007)

Understanding and improving recruitment to randomised controlled trials: Qualitative research approaches.
حسب: Elliott, D, وآخرون
منشور في: (2017)

Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protecT randomised controlled trial according to treatment received
حسب: Neal, D, وآخرون
منشور في: (2019)

Elucidation of Clathrin-Mediated Endocytosis in Tetrahymena Reveals an Evolutionarily Convergent Recruitment of Dynamin.
منشور في: (2005-11-01)

Elucidation of clathrin-mediated endocytosis in tetrahymena reveals an evolutionarily convergent recruitment of dynamin.
حسب: Nels C Elde, وآخرون
منشور في: (2005-11-01)

A review of reporting of participant recruitment and retention in RCTs in six major journals
حسب: Tomlin Zelda, وآخرون
منشور في: (2009-07-01)

Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes
حسب: Simpkin, A, وآخرون
منشور في: (2013)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
حسب: Rosario, D, وآخرون
منشور في: (2008)

Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
حسب: Collin, S, وآخرون
منشور في: (2009)